Harmony Competitors

Stocks . USA . 
Stock . Harmony Biosciences Holdings
HRMY Stock  USD 36.76  0.07  0.19%   
Harmony Biosciences competes with Vera Therapeutics, Aurinia Pharmaceuticals, Celldex Therapeutics, MannKind Corp, and Janux Therapeutics; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Harmony Biosciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Harmony Biosciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Harmony Biosciences Correlation with its peers.

Harmony Biosciences vs Sionna Therapeutics Correlation

Very weak diversification

The correlation between Harmony Biosciences Holdings and SION is 0.56 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Harmony Biosciences Holdings and SION in the same portfolio, assuming nothing else is changed.

Moving together with Harmony Stock

  0.67BMY Bristol Myers SquibbPairCorr
  0.69JNJ Johnson JohnsonPairCorr
  0.66MRK Merck CompanyPairCorr
  0.76DHT-U DRI Healthcare TrustPairCorr

Moving against Harmony Stock

  0.8000813 Dezhan HealthCarePairCorr
  0.8688185 Cansino BiologicsPairCorr
  0.73EXL Elixinol WellnessPairCorr
  0.71600079 Humanwell HealthcarePairCorr
  0.7688276 Changchun BCHT BiotePairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
34.9036.8738.84
Details
Intrinsic
Valuation
LowRealHigh
33.0842.1044.07
Details
Naive
Forecast
LowNextHigh
35.2137.1939.16
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
35.4237.7940.17
Details

Harmony Biosciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Harmony Biosciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Harmony and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Harmony Biosciences does not affect the price movement of the other competitor.

High positive correlations

ABCL
+ 0.84
BHVN
NUVB
+ 0.76
VERA
MNKD
+ 0.67
VERA
SION
+ 0.67
NUVB
NUVB
+ 0.66
AUPH
IMCR
+ 0.56
AUPH
  

High negative correlations

JANX
- 0.91
VERA
ABCL
- 0.81
AUPH
NUVB
- 0.69
ABCL
JANX
- 0.68
MNKD
BHVN
- 0.68
AUPH
NUVB
- 0.58
JANX

Risk-Adjusted Indicators

There is a big difference between Harmony Stock performing well and Harmony Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Harmony Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
VERA  3.73  0.64  0.20  0.36  3.13 
(4.58)
 10.77 
(5.81)
 23.44 
AUPH  1.80  0.28  0.11  1.44  1.99 
(2.13)
 4.73 
(3.46)
 14.95 
CLDX  2.44 (0.13) 0.00 (0.06) 0.00 
 0.00 
 6.44 
(5.22)
 13.96 
MNKD  1.99  0.02 (0.01) 0.13  2.46 
(2.58)
 4.48 
(3.73)
 17.21 
JANX  3.58 (0.58) 0.00 (0.36) 0.00 
 0.00 
 9.48 
(6.55)
 63.52 
BHVN  4.66 (0.04) 0.00  0.12  0.00 
 0.00 
 10.23 
(7.35)
 45.51 
ABCL  3.14 (0.56) 0.00 (0.18) 0.00 
 0.00 
 5.90 
(8.62)
 19.23 
NUVB  4.42  0.76  0.16  0.50  4.54 
(5.23)
 10.48 
(5.78)
 68.61 
IMCR  1.99  0.09  0.01  1.22  2.30 
(2.07)
 4.73 
(3.58)
 10.85 
SION  3.65  0.56  0.10  1.89  4.48 
(3.90)
 11.87 
(8.47)
 47.28 

Harmony Biosciences Competitive Analysis

The better you understand Harmony Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Harmony Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Harmony Biosciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
HRMY VERA AUPH CLDX MNKD JANX BHVN ABCL NUVB IMCR
 0.19 
 36.76 
Harmony
 2.52 
 47.49 
Vera
 2.22 
 14.53 
Aurinia
 3.46 
 25.92 
Celldex
 7.61 
 5.46 
MannKind
 2.18 
 14.81 
Janux
 1.82 
 13.51 
Biohaven
 8.62 
 4.24 
Abcellera
 5.41 
 5.59 
Nuvation
 0.23 
 35.11 
Immunocore
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Not too volatile
Not too volatile
Slightly risky
Somewhat reliable
Slightly risky
Moderately volatile
Risky
Very steady
Market Performance
(90 Days Performance)
Good
Good
Fair
Weakest
Weak
Weakest
Weakest
Weakest
Soft
Soft
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Low
Fair
Low
Small
Low
Low
High
Average
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Fairly Valued
Fairly Valued
Over Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Strong Buy
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Buy
Strong Buy
Strong Hold
Sell
Strong Sell
Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
4.91
8.24
13.09
12.29
3.25
21.08
0.71
9.86
33.58
3.98
Net Asset
999.2 M
655.68 M
550.64 M
792.34 M
393.84 M
1.06 B
615.11 M
1.36 B
540.63 M
1.01 B
Profit Margin
0.22
N/A
0.29
N/A
0.0932
N/A
N/A
N/A
N/A
-0.077
EBITDA
233.41 M
(144.42 M)
31.73 M
(191.9 M)
77.47 M
(96.79 M)
(877.26 M)
(204.15 M)
(566.91 M)
(38.5 M)
Operating Margin
0.27
N/A
0.4
-98.59
0.23
-3.53
N/A
-8.52
-4.3
-0.0692
Current Valuation
1.61 B
2.83 B
1.68 B
1.2 B
1.62 B
(168.17 M)
1.76 B
927.7 M
1.62 B
1.33 B
Price To Book
2.53
8.15
5.33
2.98
N/A
0.82
12.19
1.33
6.47
4.49
Retained Earnings
2.22 M
(461.25 M)
(936.57 M)
(1.56 B)
(3.2 B)
(237.76 M)
(1.35 B)
116.93 M
(910.74 M)
(795.76 M)
Current Asset
N/A
237.64 M
16.53 M
294.94 M
76.65 M
N/A
32.52 M
N/A
N/A
N/A
Beta
0.84
1.16
1.47
1.2
0.81
2.88
3.54
0.73
1.55
0.78
Number Of Employees
268
224
130
186
403
109
256
596
291
493
Shares Outstanding
57.6 M
70.99 M
131.84 M
66.45 M
307.07 M
60.15 M
132.69 M
299.34 M
341.83 M
50.53 M
Cash Flow From Operations
219.82 M
(134.68 M)
44.39 M
(157.78 M)
42.51 M
(43.81 M)
(582.45 M)
(108.56 M)
(130.41 M)
26.06 M
Total Debt
181.41 M
54.64 M
79.37 M
3.81 M
47.7 M
23.02 M
36.58 M
65.36 M
8.91 M
432.72 M
Return On Equity
0.26
-0.73
0.21
-0.32
N/A
-0.12
-5.22
-0.17
-0.52
-0.0755
Return On Asset
0.13
-0.38
0.0941
-0.22
0.0995
-0.1
-1.06
-0.1
-0.25
-0.0155
Number Of Shares Shorted
4.35 M
8.46 M
8.34 M
8.24 M
25.73 M
9.24 M
19.99 M
48.27 M
41.74 M
9.52 M
Book Value Per Share
14.5
6.24
2.77
9.01
-0.14
16.24
-0.16
3.22
0.95
7.86
Current Liabilities
N/A
54.04 M
3.62 M
30.24 M
268.32 M
N/A
3.61 M
N/A
N/A
N/A
Total Asset
999.2 M
655.68 M
550.64 M
792.34 M
393.84 M
1.06 B
615.11 M
1.36 B
540.63 M
1.01 B
Debt To Equity
0.79
0.1
0.019
0.011
9.93
0.072
0.22
0.06
0.006
0.41
Short Ratio
6.43
4.83
7.02
10.59
5.18
2.86
6.31
15.08
7.02
34.14
Target Price
46.45
75.15
16.67
53.36
9.44
63.59
20.8
9.83
11.67
66.36
Shares Owned By Institutions
90.53
99.12
50.64
99.81
55.15
93.09
65.4
36.97
66.29
99.97
Market Capitalization
2.12 B
3.46 B
1.96 B
1.72 B
1.56 B
910.64 M
1.83 B
1.39 B
2.03 B
1.77 B
Price To Earning
293.37
17.01
-4.83
-2.21
2.27
N/A
-4.25
16.67
N/A
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
-0.23
-0.98
N/A
2.22
N/A
N/A
Price To Sales
2.56
N/A
7.37
662.71
5.78
91.06
N/A
39.32
75.75
4.66
Net Income
145.49 M
(152.15 M)
5.75 M
(157.86 M)
27.59 M
(68.99 M)
(846.42 M)
(162.86 M)
(567.94 M)
(51.09 M)
Earnings Per Share
3.17
-4.25
0.56
-3.26
0.1
-1.67
-7.52
-0.62
-0.47
-0.58
Shares Owned By Insiders
12.14
0.88
6.82
0.19
1.64
6.91
9.52
22.96
19.04
0.028
Revenue
714.73 M
N/A
235.13 M
7.02 M
285.5 M
10.59 M
N/A
28.83 M
7.87 M
247.77 M
Working Capital
404.17 M
625.85 M
348.83 M
707.66 M
186.47 M
1.02 B
384.25 M
674.76 M
468.01 M
717.68 M
Cash And Equivalents
254.17 M
131.93 M
391.51 M
356.82 M
154.16 M
338.76 M
23.21 M
868.21 M
703.8 M
208.06 M
Cash Per Share
4.3
4.86
2.76
7.63
0.6
8.15
8.48
3.04
3.22
4.74
Gross Profit
641.74 M
N/A
213.08 M
(214.08 M)
235.9 M
(105.15 M)
N/A
(147.49 M)
14.51 M
334.36 M
Day Typical Price
36.78
47.56
14.72
26.12
5.62
14.93
13.59
4.37
5.71
35.07
Accumulation Distribution
0.0234
28274.62
35648.99
13391.31
371847.0
100089.0
79423.82
594987.0
451101.0
18027.95
Market Facilitation Index
0.87
0.0
0.0
0.0
N/A
0.0
0.0
N/A
N/A
0.0
Daily Balance Of Power
0.0805
(0.59)
(0.57)
(0.90)
(0.92)
(0.35)
(0.33)
(0.83)
(0.71)
0.0792
Period Momentum Indicator
0.07
(1.23)
(0.33)
(0.93)
(0.45)
(0.33)
(0.25)
(0.40)
(0.32)
0.08
Rate Of Daily Change
1.0
0.97
0.98
0.97
0.92
0.98
0.98
0.91
0.95
1.0
Day Median Price
36.78
47.6
14.81
26.23
5.71
15.0
13.64
4.43
5.78
35.05
Price Action Indicator
0.01
(0.72)
(0.45)
(0.77)
(0.47)
(0.35)
(0.25)
(0.39)
(0.35)
0.11
Coefficient Of Variation
564.39
603.46
841.92
(6,278)
5473.02
(1,630)
(10,255)
(1,085)
879.43
2302.96
Mean Deviation
1.5
3.73
1.8
2.44
1.99
3.58
4.66
3.14
4.42
1.99
Jensen Alpha
0.302
0.6388
0.2832
(0.13)
0.0202
(0.58)
(0.04)
(0.56)
0.7587
0.095
Total Risk Alpha
0.1554
0.3391
0.0558
(0.35)
(0.23)
(1.21)
(0.79)
(0.81)
0.1489
(0.14)
Sortino Ratio
0.138
0.201
0.1051
N/A
(0.01)
N/A
N/A
N/A
0.1617
0.0136
Downside Variance
3.87
12.87
4.74
N/A
7.87
N/A
N/A
N/A
25.03
5.58
Standard Deviation
1.97
4.83
2.59
3.15
2.88
7.78
7.54
4.31
7.8
2.55
Kurtosis
1.67
0.8689
2.48
0.336
2.76
33.35
12.41
1.99
22.3
(0.05)
Potential Upside
3.38
10.77
4.73
6.44
4.48
9.48
10.23
5.9
10.48
4.73
Treynor Ratio
0.6176
0.3579
1.44
(0.06)
0.13
(0.36)
0.1238
(0.18)
0.5049
1.22
Maximum Drawdown
11.3
23.44
14.95
13.96
17.21
63.52
45.51
19.23
68.61
10.85
Variance
3.89
23.29
6.69
9.94
8.32
60.48
56.83
18.54
60.91
6.49
Market Risk Adjusted Performance
0.6276
0.3679
1.45
(0.05)
0.14
(0.35)
0.1338
(0.17)
0.5149
1.23
Risk Adjusted Performance
0.136
0.1298
0.0941
(0)
0.0208
(0.04)
0.0019
(0.06)
0.0923
0.0389
Skewness
(0.50)
0.7784
0.7957
0.3041
0.4175
(4.73)
(1.89)
(0.06)
3.5
0.4672
Semi Deviation
1.6
3.13
1.99
N/A
2.46
N/A
N/A
N/A
4.54
2.3
Information Ratio
0.1375
0.1495
0.0885
(0.04)
(0.01)
(0.07)
(0.02)
(0.11)
0.1037
0.0127
Value At Risk
(2.28)
(5.81)
(3.46)
(5.22)
(3.73)
(6.55)
(7.35)
(8.62)
(5.78)
(3.58)
Expected Short fall
(1.75)
(4.58)
(2.13)
N/A
(2.58)
N/A
N/A
N/A
(5.23)
(2.07)
Downside Deviation
1.97
3.59
2.18
N/A
2.81
N/A
N/A
N/A
5.0
2.36
Semi Variance
2.57
9.77
3.97
N/A
6.07
N/A
N/A
N/A
20.65
5.27

Harmony Biosciences Competition Performance Charts

Five steps to successful analysis of Harmony Biosciences Competition

Harmony Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Harmony Biosciences in relation to its competition. Harmony Biosciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Harmony Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Harmony Biosciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Harmony Biosciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Harmony Biosciences position

In addition to having Harmony Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Consumption Thematic Idea Now

Consumption
Consumption Theme
Companies that deliver final goods such as cars or clothing for consumption by consumers. The Consumption theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumption Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Harmony Stock Analysis

When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY